CytomX Therapeutics: Three Reasons That Show It Is Down But Not Out (NASDAQ:CTMX)

oversnap/E+ through Getty Photos

Two, three years in the past, CytomX Therapeutics (NASDAQ:CTMX) was on the cusp of greatness. It had three issues going for it. First, it had a novel, conditionally activated Antibody Drug Conjugate (ADC) platform that might be used to focus on beforehand undruggable proteins. Second, it

Trial data

Trial information (CTMX web site)

Back To Top